NCT00220701View on ClinicalTrials.gov

Escitalopram in the Treatment of Dysthymic Disorder, Double Blind

PHASE4CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

November 30, 2008

Study Completion Date

January 31, 2009

Conditions

Dysthymic Disorder

Interventions

DRUG

Lexapro (escitalopram)

antidepressant drug selective serotonin reuptake inhibitor (SSRI)

Trial Locations (1)

10019

Mood Disorders Research Program, St. Luke's-Roosevelt Hospital Center, New York

Sponsors

Collaborators (1)

Forest Laboratories

All Listed Sponsors

collaborator

Forest Laboratories

INDUSTRY

lead

St. Luke's-Roosevelt Hospital Center

OTHER

NCT00220701 - Escitalopram in the Treatment of Dysthymic Disorder, Double Blind | Biotech Hunter | Biotech Hunter